NCIt definition : A glycoengineered second-generation antibody of cetuximab with potential antineoplastic
activities. Upon intravenous administration, tomuzotuximab selectively binds to the
extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing
the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated
signaling and inhibit EGFR-dependent tumor cell proliferation. Further, tomuzotuximab
has a fully human glycosylation pattern and is glyco-optimized at its Fc domain to
promote antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the
epidermal growth factor family of extracellular protein ligands, may be overexpressed
on the cell surfaces of certain tumor types.;
UNII : 5P637IXG16;
CAS number : 1646321-00-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1646321-00-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)